Navigation Links
Encorium Reports Third Quarter 2009 Financial Results; Announces Date of Annual Stockholder Meeting

BERWYN, Pa., Nov. 16 /PRNewswire-FirstCall/ -- Encorium Group, Inc. (Nasdaq: ENCO), a full service multinational clinical research organization (CRO) conducting studies in over 30 countries for many of the world's leading pharmaceutical and biotechnology companies, today announced its financial results for the third quarter ended September 30, 2009.

As previously announced, on July 16, 2009 the Company sold substantially all of the assets relating to its US line of business to Pierrel Research USA, Inc., the result of which the Company no longer has any employees or significant operations in the United States. Due to this sale, for the three and nine months ended September 30, 2009 and 2008, the results of the U.S. business have been presented as discontinued operations in the Company's consolidated financial statements.

Net revenue for the third quarter of 2009 was $4.5 million, a decrease of 17.6% from $5.4 million for the third quarter of 2008. The decrease in net revenues was primarily attributable to unfavorable foreign currency fluctuations of $200,000 for the three months ended September 30, 2009. Approximately $650,000 was attributable to revenue recognized on a contract that completed in 2008. The Company had a consolidated backlog at September 30, 2009 from continuing operations of $19.9 million which included approximately $8.3 million of new business wins in the first nine months of 2009 compared to a backlog of $27.0 million at September 30, 2008.

Direct expenses for the third quarter of 2009 were $2.9 million, or 56.9% of net revenues, compared to $3.5 million, or 54.0% of net revenues, for the comparable prior year period. The decrease in direct expenses was primarily the result of approximately $156,000 of favorable foreign currency fluctuations combined with reductions in staff and subcontractors utilized on active clinical studies being conducted, net of severance and other costs.

Selling, general, and administrative expenses (SG&A) was $2.1 million, or 40.3% of net revenue, for the three months ended September 30, 2009, compared to $2.0 million, or 31.3% of net revenue, for the three months ended September 30, 2008.

Depreciation and amortization expense decreased 75.6% to $98,563 for the three months ended September 30, 2009 from $403,406 for the three months ended September 30, 2009 primarily as a result of certain intangible assets acquired as part of the Encorium Oy (formerly Remedium) acquisition being fully amortized. During the three months ended September 30, 2008, the Company took a non-cash impairment charge of $1.86 million in connection with its analysis of the carrying value of goodwill acquired in connection with the acquisition of Encorium Oy.

Loss from continuing operations decreased to $643,389 or $(0.04) per diluted share for the third quarter of 2009, from a net loss of $2.4 million, or $(0.12) per diluted share, in the third quarter of 2008.

Financial Position

Encorium's balance sheet at September 30, 2009 reflected cash and cash equivalents of $318,243 and stockholders' equity of $925,423. Our net cash used in operations for the nine months ended September 30, 2009 was $5.4 million. The Company's latest financials have been prepared on a going concern basis. As previously disclosed, Encorium's independent registered public accounting firm reported that the Company's audited consolidated financial statements for the fiscal year ended December 31, 2008, included in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on April 27, 2009, contains a paragraph that indicates that, while the Company's financial statements have been prepared on a going concern basis, there is substantial doubt about its ability to continue as a going concern, and that no adjustments have been made to the financial statements that might result from the outcome of this uncertainty.

On October 19, 2009, the Company completed a private placement of 3,937,500 shares of our common stock with a private investor for an aggregate purchase price of $1,575,000, or $.40 per share. Prior to the transaction, the Company entered into Warrant Exchange Agreements with two investors (the "Investors") pursuant to which the Company issued to the Investors an aggregate of 1,864,000 shares of Common Stock (collectively, the "Exchange Shares") and warrants to purchase an aggregate of 874,126 shares of Common Stock, exercisable for a period of five years, at an exercise price of $.40 per share (collectively, the "Exchange Warrants"). The Exchange Shares and Exchange Warrants were issued in exchange for warrants dated as of May 9, 2007 held by the Investors to purchase an aggregate of 874,126 shares of Common Stock of the Company (collectively, the "Original Warrants"). Except as described above, the terms of the Exchange Warrants, including anti-dilution adjustments, are substantially similar to those of the Original Warrants.

The Company also announced on October 19, 2009, that it has terminated previously announced negotiations for the sale of the Company's wholly-owned subsidiary Encorium OY to a clinical research organization based in the United States and will not pursue a sale of the Company or Encorium Oy at this time.

The Company anticipates that will meet its cash requirements at least into the second quarter of 2010, assuming it is able to fully implement its current costs cutting initiatives, it is able to win additional contracts during fiscal 2009 and it is able to maintain current customer contracts. We will continue to seek strategic alternatives, including, but not limited to attempting to secure additional financing. The Company's ability to obtain additional financing in the future will depend in part upon prevailing capital market conditions, as well as conditions in its business and its operating results; and those factors may affect the Company's efforts to arrange additional financing on terms that are satisfactory to it or at all. If Encorium is unable to secure additional financing on terms acceptable to it and on a timely basis, it may significantly reduce its operating costs, which may include the cessation of operations in some countries. The Company's consolidated financial statements do not include any adjustment to reflect the possible future effects on the recoverability or classification of assets or the amounts and classification of liabilities that may result from the outcome of its ability to continue as a going concern.

Dr. Kai Lindevall, executive chairman stated, "We are very pleased that we were recently able to shore up our balance sheet. While additional financing is likely necessary, we believe our experience and capabilities in the vaccine field coupled with the recent new awards in this area demonstrate the long term potential we have to grow into a leading vaccine franchise with expertise in pre-clinical support, regulatory consultancy and strategic trial planning."

Annual Meeting of Stockholders

The Board of Directors of Encorium Group, Inc. has set January 8, 2010 as the date of the Annual Meeting of Stockholders. A proxy statement, which will discuss in detail matters that will be presented at the Annual Meeting, and an Annual Report will be sent to all Stockholders prior to the date of the Annual Meeting.

Conference Call

Encorium has elected to not hold a quarterly conference call at this time.

About Encorium Group, Inc.

Encorium Group, Inc. is a global clinical research organization specializing in the design and management of complex clinical trials and Patient Registries for the pharmaceutical, biotechnology and medical device industries. The Company's mission is to provide its clients with high quality, full-service support for their biopharmaceutical and medical device development programs. Encorium offers therapeutic expertise, experienced team management and advanced technologies. The Company has drug and biologics development as well as clinical trial experience across a wide variety of therapeutic areas such as infectious diseases, cardiovascular, vaccines, oncology, diabetes endocrinology/metabolism, gene therapy, immunology, neurology, gastroenterology, dermatology, hepatology, women's health and respiratory medicine. Encorium believes that its expertise in the design of complex clinical trials, its therapeutic experience and commitment to excellence, and its application of innovative technologies, offer its clients a means to more quickly and cost effectively move products through the clinical development process.

This press release contains forward-looking statements identified by words such as "estimate," "project," "expect," "intend," "believe," "anticipate" and similar expressions. Those statements involve risks and uncertainties, and actual results could differ materially from those discussed. Factors that could cause or contribute to such differences include, but are not limited to: (i) the risk that we may not have sufficient funds to operate our business; (ii) our success in attracting new business and retaining existing clients and projects; (iii) the size, duration and timing of clinical trials we are currently managing may change unexpectedly; (iv) the termination, delay or cancellation of clinical trials we are currently managing could cause revenues and cash-on-hand to decline unexpectedly; (v) the timing difference between our receipt of contract milestone or scheduled payments and our incurring costs to manage these trials; (vi) outsourcing trends in the pharmaceutical, biotechnology and medical device industries; (vii) the ability to maintain profit margins in a competitive marketplace; (viii) our ability to attract and retain qualified personnel; (ix) the sensitivity of our business to general economic conditions; (x) other economic, competitive, governmental and technological factors affecting our operations, markets, products, services and prices; (xi) announced awards received from existing and potential customers are not definitive until fully negotiated contracts are executed by the parties; (xii) our backlog may not be indicative of future results and may not generate the revenues expected; (xiii) uncertainties regarding the availability of additional capital; and (xiv) uncertainties regarding the continued listing of our common stock on Nasdaq. You should not place undue reliance on any forward-looking statement. We undertake no obligation to publicly release the result of any revision of these forward-looking statements to reflect events or circumstances after the date they are made or to reflect the occurrence of unanticipated events. Please refer to the section entitled "Risk Factors" in the Company Annual Report on Form 10-K for the year ended December 31, 2008, the Company's Quarterly Report on Form 10-Q for the period ended June 30, 2009; and the Company's Quarterly Report on Form 10-Q for the period ended September 30, 2009 for a more complete discussion of factors which could cause our actual results and financial position to change.

                           --financial tables to follow--

                                ENCORIUM GROUP, INC.

                                  Three Months Ended       Nine Months Ended
                                     September 30,            September 30,
                                  2009         2008         2009        2008
                                  ----         ----         ----        ----

        Net revenue         $4,446,606   $5,396,894  $13,468,042  $16,716,964
         revenue               661,176    1,116,818    2,576,542    3,085,554
                               -------    ---------    ---------    ---------
    Total Revenue            5,107,782    6,513,712   16,044,584   19,802,518
                             ---------    ---------   ----------   ----------
    Operating Expenses
        Direct               2,905,878    3,519,946    9,270,853   11,026,826
         expenses              661,176    1,116,818    2,576,542    3,085,554
        Selling, general
         and administrative  2,058,878    2,035,638    6,379,746    6,836,465
         and amortization       98,563      403,406      281,938    1,183,681
        Impairment loss              -    1,856,183            -    1,856,183
                                   ---    ---------          ---    ---------
    Total Operating
     Expenses                5,724,495    8,931,991   18,509,079   23,988,709
                             ---------    ---------   ----------   ----------

    Loss from
     Operations               (616,713)  (2,418,279)  (2,464,495)  (4,186,191)

         Interest Income             -        1,071            -       13,756
         Interest Expense      (26,676)     (17,129)     (31,132)     (24,044)
                               -------      -------      -------      -------
    Net Interest (Expense)
     Income                    (26,676)     (16,058)     (31,132)     (10,288)

    Other expense                    -            -            -            -

    Net Loss from continuing
     operations before
     Income Taxes             (643,389)  (2,434,337)  (2,495,627)  (4,196,479)
                             ---------  -----------   ----------  -----------

    Income Tax Expense
     (Benefit)                  98,826       (8,627)      90,899       60,269
                                ------       ------       ------       ------

    Net Loss from
     operations              $(742,215) $(2,425,710) $(2,586,526) $(4,256,748)
                             =========  ===========  ===========  ===========

    Net loss from
     operations               (258,436)  (1,455,642)    (554,016)  (3,077,435)

    Income Tax Expense
     (Benefit)                       -            -            -            -
                                   ---          ---          ---          ---

    Net Loss               $(1,000,651) $(3,881,352) $(3,140,542) $(7,334,183)
                           ===========  ===========  ===========  ===========

    Weighted Average
     Common and Common
     Equivalent Shares

    Basic                   20,523,883   20,603,140   20,523,883   20,603,140
    Diluted                 20,523,883   20,603,140   20,523,883   20,603,140

    Net Loss per Common
    Continuing Operations       $(0.04)      $(0.12)      $(0.13)      $(0.21)
    Discontinued Operations     $(0.01)      $(0.07)      $(0.02)      $(0.15)
                                ------       ------       ------       ------

    Net Loss per Common
     Share                      $(0.05)      $(0.19)      $(0.15)      $(0.36)
                                ======       ======       ======       ======

            See accompanying notes to the consolidated financial statements

                                   ENCORIUM GROUP, INC.

                                                 September 30, December 31,
                                                     2009         2008
                                                     ----         ----
    Current Assets
       Cash and cash equivalents                   $318,243   $5,705,818
       Investigator advances                         29,289    1,088,768
       Accounts receivable, less allowance of
        $220,000 and $97,000 for September 30,
        2009 and December 31, 2008, respectively  3,137,422    4,624,161
       Prepaid expenses and other                 1,133,838    1,206,088
       Prepaid taxes                                 40,670       28,290
       Costs and estimated earnings in
        excess of related billings on
        uncompleted contracts                     1,311,739    1,443,427
                                                  ---------    ---------
                        Total Current Assets      5,971,201   14,096,552
                                                  ---------   ----------

    Property and Equipment, Net                     303,940    1,211,929

    Intangible Assets
       Goodwill                                   1,414,244    1,366,269
       Other intangibles, Net                     3,613,698    3,733,517
       Other assets                                 314,992      684,666

    Total Assets                                $11,618,075  $21,092,933
                                                ===========  ===========

    Liabilities and Stockholders' Equity
    Current Liabilities
       Accounts payable                          $2,684,547   $3,624,071
       Notes payable                                701,335            -
       Accrued expenses                           2,671,716    3,004,627
       Deferred taxes                               612,987      206,173
       Obligations under capital leases              48,154       72,542
       Billings in excess of related costs
        and estimated earnings on
        uncompleted contracts                     1,418,607    3,307,347
       Customer advances                          1,409,074    5,297,000
                                                  ---------    ---------
                   Total Current Liabilities      9,546,420   15,511,760
                                                  ---------   ----------

    Long Term Liabilities
       Obligations under capital leases              79,268      189,680
       Deferred taxes                               842,250      897,204
       Other liabilities                            224,714      316,516
                                                    -------      -------
                   Total Long Term Liabilities    1,146,232    1,403,400
                                                  ---------    ---------
    Total Liabilities                            10,692,652   16,915,160
                                                 ----------   ----------

    Stockholders' Equity
       Common stock, $.001 par value
        35,000,000 shares authorized,
        20,834,004 shares issued and
        20,523,883 shares outstanding,
        respectively                                 20,834       20,834
       Additional paid-in capital                32,716,837   32,417,250
       Additional paid-in capital warrants          905,699      905,699
       Accumulated deficit                      (32,877,972) (29,737,430)
       Accumulated other comprehensive income       886,714    1,298,109
                                                    -------    ---------
        Less:                                     1,652,112    4,904,462
         Treasury stock, at cost, 310,121
          shares                                   (726,689)    (726,689)
                                                   --------     --------
                   Total Stockholders' Equity       925,423    4,177,773
                                                    -------    ---------

    Total Liabilities and Stockholders'
     Equity                                     $11,618,075  $21,092,933
                                                ===========  ===========

           See accompanying notes to the consolidated financial statements.

SOURCE Encorium Group, Inc.

SOURCE Encorium Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Encorium Appoints Shahab Fatheazam to its Board of Directors
2. Encorium Announces Receipt of Letter from Nasdaq Regarding its 2008 Form 10-K Filing
3. Encorium Reports Fourth Quarter and Full Year 2008 Financial Results
4. Encorium Group Enters into Non-Binding Letters of Intent
5. Encorium Reports First Quarter 2009 Financial Results
6. Encorium Group Amends LOI with Respect to the Sale of its U.S. Business;
7. Encorium Receives NASDAQ Deficiency Letter Regarding Stockholders Equity
8. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
9. Haemacure Reports Third Quarter 2007 Results
10. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
11. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
Post Your Comments:
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest ... its plans to open a flagship location in Covington, LA at 401 N. U.S. ... Go store next to Office Depot in the Holiday Square shopping center. Its location ...
(Date:10/12/2017)... ... 12, 2017 , ... IsoComforter, Inc. ( ), one of ... innovative new design of the shoulder pad. The shoulder pad provides optimal support ... your pain while using cold therapy. By utilizing ice and water that is circulated ...
(Date:10/12/2017)... ... , ... Asante, a nationally recognized health system in southern ... home health joint venture through an agreement, effective October 1, 2017, to create ... health company with Asante, delivering clinically integrated care, for the past eight years. ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... Hair Restoration, has recently contributed a medical article to the newly revamped ... Dr. Mohebi’s article spotlights the hair transplant procedure known as Follicular Unit ...
(Date:10/12/2017)... ... ... Leading pediatric oncology experts at Children’s National Health System will ... the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by Jeffrey ... Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief of the Division ...
Breaking Medicine News(10 mins):
(Date:9/19/2017)... HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that ... developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D and ...
(Date:9/18/2017)... 18, 2017 EpiVax, Inc. ("EpiVax") ... and immune engineering, today announced a new ... (H7N9) vaccine. ... influenza and presents a challenge for traditional ... to be effective. Using state-of-the-art bioinformatics and molecular ...
(Date:9/12/2017)... , Sept. 12, 2017  Consumer reviews on the independent ... as the number one company for hearing aids, ranking it ... fifteen other brands. ... Hearing Named #1 by Consumers For Hearing Aids ... Embrace Hearing is an online store that provides high performance, ...
Breaking Medicine Technology: